C Hohberg

1.1k total citations
31 papers, 929 citations indexed

About

C Hohberg is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, C Hohberg has authored 31 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in C Hohberg's work include Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (10 papers). C Hohberg is often cited by papers focused on Diabetes Treatment and Management (14 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (10 papers). C Hohberg collaborates with scholars based in Germany, Denmark and Japan. C Hohberg's co-authors include Thomas Först, Andreas Pfützner, G Lübben, Thomas R. Konrad, Peter Herbert Kann, Matthias Langenfeld, S Först, T. Kunt, Volkmar H.R. Schmid and A Pfützner and has published in prestigious journals such as Circulation, Diabetes Care and Atherosclerosis.

In The Last Decade

C Hohberg

29 papers receiving 882 citations

Peers

Countries citing papers authored by C Hohberg

Since Specialization

Citations

This map shows the geographic impact of C Hohberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Hohberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Hohberg more than expected).

Fields of papers citing papers by C Hohberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Hohberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Hohberg. The network helps show where C Hohberg may publish in the future.

Co-authorship network of co-authors of C Hohberg

This figure shows the co-authorship network connecting the top 25 collaborators of C Hohberg. A scholar is included among the top collaborators of C Hohberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Hohberg. C Hohberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zwei Insulin-glargin-Formulierungen im Vergleich 2016 ·MMW - Fortschritte der Medizin ·(unknown), Nanette C. Schloot, C Hohberg, Tobias Wiesner, Lutz Heinemann	1
2	Anforderungen an Biosimilars und biosimilares Insulin 2015 ·Diabetologie und Stoffwechsel ·(unknown), Nanette C. Schloot, C Hohberg, Tobias Wiesner, Lutz Heinemann	1
3	Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β ‐cell protection in individuals with type 2 diabetes 2010 ·Diabetes Obesity and Metabolism ·Thomas Först, Martin Larbig, C Hohberg, S Först, (unknown), (unknown), (unknown), A Pfützner	15
4	Limitations of the HOMA-B Score for Assessment of β -Cell Functionality in Interventional Trials—Results from the PIOglim study 2010 ·Diabetes Technology & Therapeutics ·Andreas Pfützner, Michael Derwahl, Stephan Jacob, C Hohberg, (unknown), Ute Lehmann, W Fuchs, Thomas Först	16
5	Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus 2010 ·Clinical Science ·Thomas Först, Matthias M. Weber, M Löbig, Ute Lehmann, Jürgen Müller, C Hohberg, (unknown), W Fuchs, Andreas Pfützner	10
6	Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β‐cell function: results from the PioSwitch Study 2009 ·Diabetes Obesity and Metabolism ·C Hohberg, Andreas Pfützner, Thomas Först, G Lübben, Efstratios Karagiannis, (unknown), Thomas Schöndorf	16
7	Time–Action Profile and Patient Assessment of Inhaled Insulin via the Exubera Device in Comparison with Subcutaneously Injected Insulin Aspart via the FlexPen Device 2009 ·Diabetes Technology & Therapeutics ·Thomas Först, C Hohberg, Thomas Schöndorf, (unknown), S Först, (unknown), (unknown), Andreas Pfützner	9
8	Cardiovascular Effects of Disturbed Insulin Activity in Metabolic Syndrome and in Type 2 Diabetic Patients 2009 ·Hormone and Metabolic Research ·Thomas Först, C Hohberg, Andreas Pfützner	25
9	Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling Study in patients with type 2 diabetes 2008 ·Clinical Therapeutics ·(unknown), C Hohberg, A Pfützner, Christina Mørup Jørgensen, Klaus H. Jensen, (unknown), (unknown)	22
10	Reliability of Lightguide Spectrophotometry (O2C®) for the Investigation of Skin Tissue Microvascular Blood Flow and Tissue Oxygen Supply in Diabetic and Nondiabetic Subjects 2008 ·Journal of Diabetes Science and Technology ·Thomas Först, C Hohberg, (unknown), S Först, Peter Herbert Kann, Andreas Pfützner	70
11	Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study 2007 ·Hormone and Metabolic Research ·Andreas Pfützner, M Hanefeld, G Lübben, M. A. Weber, Efstratios Karagiannis, (unknown), C Hohberg, Thomas Först	28
12	Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease 2007 ·Atherosclerosis ·Thomas Först, Efstratios Karagiannis, G Lübben, C Hohberg, Thomas Schöndorf, Gerhard Dikta, (unknown), Michael Morcos, Wilfried Dänschel, (unknown), Andreas Pfützner	36
13	Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study 2007 ·Metabolism ·Thomas Först, Andreas Pfützner, G Lübben, Matthias M. Weber, Nikolaus Marx, Efstrathios Karagiannis, Carsta Koehler, (unknown), C Hohberg, M Hanefeld	60
14	Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus 2007 ·Gynecological Endocrinology ·Thomas Schöndorf, G Lübben, Markus Hoopmann, (unknown), Thomas Först, C Hohberg, M Löbig, (unknown), (unknown), (unknown), (unknown)	10
15	Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus. 2007 ·PubMed ·Thomas Schöndorf, Thomas Först, C Hohberg, G Lübben, Franz Paul Armbruster, (unknown), (unknown), (unknown), M Löbig, (unknown), Andreas Pfützner	1
16	Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus 2006 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Andreas Pfützner, Eberhard Standl, (unknown), Jan Schulze, C Hohberg, G Lübben, (unknown), Thomas Schöndorf, Thomas Först	23
17	Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control 2005 ·Hormone and Metabolic Research ·Andreas Pfützner, C Hohberg, G Lübben, (unknown), (unknown), Peter Herbert Kann, Thomas Först	33
18	IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design 2005 ·Diabetes Technology & Therapeutics ·Andreas Pfützner, Eberhard Standl, C Hohberg, Thomas R. Konrad, (unknown), G Lübben, Matthias Langenfeld, Jan Schulze, Thomas Först	24
19	IRIS II study: the IRIS II score—assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes 2004 ·Diabetic Medicine ·Thomas Först, Eberhard Standl, C Hohberg, Thomas R. Konrad, Jan Schulze, (unknown), G Lübben, (unknown), (unknown), Matthias Langenfeld, Andreas Pfützner	13
20	Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes 2004 ·Diabetes Care ·Andreas Pfützner, T. Kunt, C Hohberg, (unknown), (unknown), Thomas R. Konrad, G Lübben, Thomas Först	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact